Abstract
Oncolytic virus therapy has recently been recognized as a promising new treatment option for cancer. The strategy is to use genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells, without harming normal cells. Herpes simplex virus type 1 (HSV-1) has been well studied and has many advantages for the use in cancer therapy, making it the mainstay of current clinical trials of oncolytic virus therapy. Numerous preclinical and clinical studies of oncolytic HSV-1 have demonstrated its safety and antitumor efficacy, the latter of which is mainly attributable to its direct cytocidal effect. However, recent studies have also suggested that oncolytic HSV-1 elicits host antitumor immunity and induces immunogenic cancer cell death, thus offering possibilities for multifaceted strategies by focusing on enhancement of host anticancer immunity. In this review, we summarize the history and current status of preclinical and clinical studies of oncolytic virus therapy using HSV-1.
Keywords: Clinical trial, G47Δ, genetically engineered, herpes simplex virus, HSV-1, oncolytic virus.
Current Cancer Therapy Reviews
Title:New Generation of Oncolytic Herpes Virus
Volume: 11 Issue: 3
Author(s): Hiroshi Fukuhara and Tomoki Todo
Affiliation:
Keywords: Clinical trial, G47Δ, genetically engineered, herpes simplex virus, HSV-1, oncolytic virus.
Abstract: Oncolytic virus therapy has recently been recognized as a promising new treatment option for cancer. The strategy is to use genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells, without harming normal cells. Herpes simplex virus type 1 (HSV-1) has been well studied and has many advantages for the use in cancer therapy, making it the mainstay of current clinical trials of oncolytic virus therapy. Numerous preclinical and clinical studies of oncolytic HSV-1 have demonstrated its safety and antitumor efficacy, the latter of which is mainly attributable to its direct cytocidal effect. However, recent studies have also suggested that oncolytic HSV-1 elicits host antitumor immunity and induces immunogenic cancer cell death, thus offering possibilities for multifaceted strategies by focusing on enhancement of host anticancer immunity. In this review, we summarize the history and current status of preclinical and clinical studies of oncolytic virus therapy using HSV-1.
Export Options
About this article
Cite this article as:
Fukuhara Hiroshi and Todo Tomoki, New Generation of Oncolytic Herpes Virus, Current Cancer Therapy Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573394712666160128201756
DOI https://dx.doi.org/10.2174/1573394712666160128201756 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Investigation of in Vitro Release Dynamics of Cisplatin from Genipin Crosslinked Gelatin Nanocarriers
Drug Delivery Letters Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews A Review of the Diagnostic Scope of Biomarker Techniques, Genetic Screening and Virtual Scanning
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Combinatorial Chemistry & High Throughput Screening MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews Gadolinium Oxide Nanoparticles as Potential Multimodal Imaging and Therapeutic Agents
Current Topics in Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Molecular Cloning of a Novel PPEF-1 Gene Variant from a T-Cell Lymphoblastic Lymphoma Cell Line
Recent Patents on DNA & Gene Sequences Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Synthetic Nanocarriers for Intracellular Protein Delivery
Current Drug Metabolism Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets Synthesis and Evaluation of Novel Erucin Analogues as Potential Antitumor Compounds
Letters in Organic Chemistry A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer
Current Pharmaceutical Design